Barclays PLC Regeneron Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 3,000 shares of REGN stock, worth $2.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,000
Previous 3,600
16.67%
Holding current value
$2.11 Million
Previous $3.79 Million
43.54%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding REGN
# of Institutions
1,490Shares Held
85.7MCall Options Held
1.53MPut Options Held
1.44M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.53 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.94 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$4.96 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$3.4 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.33 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $75.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...